- Home
- CLCO vs VERV Comparison
CLCO vs VERV Comparison
Compare CLCO & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLCO
- VERV
- Stock Information
- Founded
- CLCO 2018
- VERV 2018
- Country
- CLCO United Kingdom
- VERV United States
- Employees
- CLCO N/A
- VERV N/A
- Industry
- CLCO
- VERV Medicinal Chemicals and Botanical Products
- Sector
- CLCO
- VERV Health Care
- Exchange
- CLCO Nasdaq
- VERV Nasdaq
- Market Cap
- CLCO 353.6M
- VERV 384.2M
- IPO Year
- CLCO N/A
- VERV 2021
- Fundamental
- Price
- CLCO $6.51
- VERV $4.57
- Analyst Decision
- CLCO
- VERV Strong Buy
- Analyst Count
- CLCO 0
- VERV 6
- Target Price
- CLCO N/A
- VERV $25.75
- AVG Volume (30 Days)
- CLCO 112.0K
- VERV 2.9M
- Earning Date
- CLCO 05-21-2025
- VERV 05-14-2025
- Dividend Yield
- CLCO 9.85%
- VERV N/A
- EPS Growth
- CLCO N/A
- VERV N/A
- EPS
- CLCO 1.31
- VERV N/A
- Revenue
- CLCO $320,759,000.00
- VERV $59,613,000.00
- Revenue This Year
- CLCO $2.03
- VERV $6.18
- Revenue Next Year
- CLCO N/A
- VERV N/A
- P/E Ratio
- CLCO $4.55
- VERV N/A
- Revenue Growth
- CLCO N/A
- VERV 271.44
- 52 Week Low
- CLCO $4.51
- VERV $2.87
- 52 Week High
- CLCO $13.15
- VERV $9.31
- Technical
- Relative Strength Index (RSI)
- CLCO 59.81
- VERV 49.94
- Support Level
- CLCO $5.91
- VERV $3.89
- Resistance Level
- CLCO $6.21
- VERV $4.63
- Average True Range (ATR)
- CLCO 0.22
- VERV 0.42
- MACD
- CLCO -0.02
- VERV 0.03
- Stochastic Oscillator
- CLCO 68.48
- VERV 56.20
About CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.